Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Relation Therapeutics, Stripe, and 370+ companies. 5-min read every Tuesday.
Machine learning-driven drug discovery company mapping human disease biology at single-cell resolution.
| Industry | Biotechnology |
| Stage | Series B |
| IPO Status | Private |
| Valuation | $300M |
| Total Funding | $50M |
| Headquarters | London, UK |
Stripe is a global financial infrastructure platform for businesses. Following its May 2026 IPO, the company is publicly traded on the NYSE with a market cap exceeding $180B.
| Industry | Fintech |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $159B |
| Total Funding | $9.4B |
| Headquarters | San Francisco, CA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Relation Therapeutics is valued at $300M. Stripe is valued at $159B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Relation Therapeutics has raised $50M. Stripe has raised $9.4B.
Relation Therapeutics is currently private. Stripe is currently private. Track both on TechStackIPO for S-1 filings and IPO announcements.
Relation Therapeutics operates in Biotechnology, while Stripe operates in Fintech.
Relation Therapeutics is a Biotechnology company valued at $300M with $50M raised. Stripe is a Fintech company valued at $159B with $9.4B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Relation Therapeutics and Stripe through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.